Human Apolipoprotein C-I (Apo C1) ELISA Kit

$407.00

Catalog Number: EA8011-2

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.
Product Size:96 Well Plate

Additional information

Format

Sandwich ELISA

Entrez Gene

341

Components

Biotinylated Human Apolipoprotein C-I Antibody, Chromogen Substrate (1x), EIA Diluent Concentrate (10x), Human Apolipoprotein C-I Microplate, Human Apolipoprotein C-I Standard, Sealing Tapes, SP Conjugate (100x), Stop Solution (1x), Wash Buffer Concentrate (20x)

TIme

4 hours

Sensitivity

25 ng/ml

Range

0.031 – 2 ug/ml

Samples Type

Plasma, Serum

Associated Disease

Cancer, Cardiovascular, Heart Disease

Species

Human

UniProt

P02654

Storage

Refer to component labels for details

Plex

1

Usage

For Research Use Only, Not To Be Used For Diagnostic Purposes

Documentation

Publications citing Assaypro: Human Apolipoprotein C-I (Apo C1) ELISA Kit... (14 results)

Please use discretion when following external links; Assaypro cannot guarantee the validity and security of all citation links provided.

Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer’s disease

Examination of external and internal factors for the pathophysiology of pediatric idiopathic steroid-sensitive nephrotic syndrome

Protective effect of inulin and the integrity of the microvasculature in diabetes mellitus

Apolipoprotein C-I Levels Are Associated with the Urinary Protein/Urinary Creatinine Ratio in Pediatric Idiopathic Steroid-Sensitive Nephrotic Syndrome: A Case Control Study

Apolipoprotein C-I Levels Are Associated with the Urinary Protein/Urinary Creatinine Ratio in Pediatric Idiopathic Steroid-Sensitive Nephrotic Syndrome: A Case Control Study

Plasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathway

Plasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathway

Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping

A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach

MALDI-Based Serum Peptide Signature Discriminating Stomach and Pancreas Adenocarcinoma Patients from Cancer-Free Controls: Adjustment to Diagnosis with Immuno-Based Assays

Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays

The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis

Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis

Loading data...